A research team from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM and the Hannover Medical School (MHH) have made significant progress in developing a new antiviral therapy. The drug, which is inhaled, uses RNAi to target and deactivate parainfluenza viruses before they multiply.